资讯

南旧金山 - 根据 InvestingPro 数据显示,过去一年股价上涨超过58%的Assembly Biosciences, Inc. (NASDAQ: ASMB )周五宣布了其用于治疗单纯疱疹病毒 (HSV)的研究性药物ABI-5366的1b期研究中期结果呈阳性,显示该药物能显著减少复发性生殖器疱疹患者的病毒脱落和生殖器病变。
Investing.com - H.C. Wainwright周一开始对Assembly Biosciences (NASDAQ:ASMB)的覆盖,给予"买入"评级和50.00美元的目标价。根据InvestingPro数据,该股目前交易价格为25.44美元,过去六个月表现强劲,上涨了104%。 该研究公司指出,Assembly的临床阶段抗病毒产品线通过与吉利德科学公司的合作有望带来显著价值。该产品 ...
Speaking at a conference titled "Namibia's Constitution amidst Reflection, Reform, and Renewal," Kuugongelwa-Amadhila praised the constitution as a "moral compass" leading the nation from a system of ...
Itanagar, Aug 18 (UNI) The Arunachal Pradesh Legislative Assembly today held a Special Session to mark the Golden Jubilee of the House, commemorating its 50-year legislative journey since the first si ...